KLK3 and pachyonychia congenita: Overall, in a phase II study of 30 patients with PC (29 with CRPC, 23 of which had been treated with prior chemotherapy), a clinical benefit was shown in 40% of patients with an endpoint of a decrease in PSA without clinical progression.